Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Exagen Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Exagen kazanç ve gelirinin sırasıyla yıllık 12.7% ve 12.5% oranında artması tahmin edilirken, EPS'nin yıllık 14.2% oranında büyümesi bekleniyor.

Anahtar bilgiler

12.7%

Kazanç büyüme oranı

14.2%

EPS büyüme oranı

Biotechs kazanç büyümesi28.6%
Gelir büyüme oranı12.5%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Good

Son güncelleme06 Aug 2024

Gelecekteki son büyüme güncellemeleri

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Aug 07
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Mar 22
Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Recent updates

Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Sep 06
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Aug 07
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Jul 13
Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

May 21
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Mar 26
Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Mar 22
Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

Jul 21
Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

Exagen appoints John Aballi as CEO

Oct 17

Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Aug 10
Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Jul 26
Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Apr 05
Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Dec 03
Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Aug 06
Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Apr 07
Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Mar 03
Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Exagen issues preliminary testing revenue ahead of ICT chat

Jan 11

Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Jan 05
Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Exagen (XGN) Investor Presentation - Slideshow

Nov 20

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:XGN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202675-13-4-85
12/31/202565-16-11-126
12/31/202457-17-15-176
6/30/202457-17-6-6N/A
3/31/202456-19-14-14N/A
12/31/202353-24-15-14N/A
9/30/202352-32-30-29N/A
6/30/202353-35-34-32N/A
3/31/202346-45-37-33N/A
12/31/202246-47-36-32N/A
9/30/202245-40-37-32N/A
6/30/202243-39-36-31N/A
3/31/202248-31-28-25N/A
12/31/202148-27-23-20N/A
9/30/202148-23-19-18N/A
6/30/202147-20-16-15N/A
3/31/202143-17-16-15N/A
12/31/202042-17-15-14N/A
9/30/202040-17-15-14N/A
6/30/202039-29-14-14N/A
3/31/202041-31-11-11N/A
12/31/201940-30-10-10N/A
9/30/201940-31-8-8N/A
6/30/201938-18-9-8N/A
3/31/201935-18-8-8N/A
12/31/201832-18-9-9N/A
12/31/201727-33N/A-11N/A
12/31/201518-21N/A-12N/A
9/30/201518-21N/A-11N/A
6/30/201517-23N/A-10N/A
3/31/201515-17N/A-10N/A
12/31/201412-17N/A-11N/A
9/30/20149-23N/A-11N/A
6/30/20146-21N/A-10N/A
3/31/20144-19N/A-8N/A
12/31/20133-18N/A-7N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: XGN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: XGN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: XGN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: XGN şirketinin gelirinin (yıllık 12.5% ) US pazarından (yıllık 8.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: XGN şirketinin gelirinin (yıllık 12.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: XGN 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok


Büyüyen şirketleri keşfedin